“Association of OPRM1 and COMT Single Nucleotide Polymorphisms with Hospital Length

of Hospital Stay and Treatment of Neonatal Abstinence Syndrome”

“Association of OPRM1 and COMT Single Nucleotide Polymorphisms with Hospital Length

of Hospital Stay and Treatment of Neonatal Abstinence Syndrome”

E Wachman, M Hayes, M Brown, J Paul, K Harvey-Wilkes, N Terrin, G Huggins, JV Aranda, and JM Davis

JAMA Media BriefingApril 30, 2013

DisclosuresDisclosures

No Conflicts of Interest

This study was supported in part by NIH funding: DA024806-01A2 to Dr. Marie Hayes

and R01DA032889-01A1 to Dr. Jonathan Davis

Neonatal Abstinence SyndromeNeonatal Abstinence Syndrome

• Opioid exposure in pregnancy - 5.6 infants/1,000 births

• Incidence has tripled in the past decade• The mother may also be smoking or taking

other medications • Signs of withdrawal in 60-80% of infants

exposed to opioids• Dysfunction of the central nervous system,

gastrointestinal tract, and/or respiratory system

Neonatal Abstinence Syndrome Neonatal Abstinence Syndrome

• Prolonged treatment in hospital, high healthcare costs

• Safety and efficacy of agents not well established

• Significant variability in the incidence and severity

• Factors influencing this variability are unknown

Neonatal Abstinence SyndromeNeonatal Abstinence Syndrome

• Genetic factors may be important

• Single nucleotide polymorphisms (SNPs): Single base pair changes that can alter protein’s function

• SNPs influence opioid dosing, metabolism, and addiction in adults

• No prior studies of genetic links to NAS

Candidate Genes for NASCandidate Genes for NAS

• SNPs present in 40-50% of the population have been studied in adults

• Mu Opioid Receptor (OPRM1) = Site of Action• 118A>G SNP

• Multi-Drug Resistance Gene (ABCB1) = Transporter• 1236C>T SNP• 3435C>T SNP• 2677G/T/A SNP

• Catechol-O-methyltransferase (COMT) = Modulator• 158A>G SNP

ObjectiveObjective

• Do SNPs in the OPRM1, ABCB1, and/or COMT genes influence length of hospital stay (LOS) and need for treatment in infants exposed to opioids during pregnancy

• Outcome Measures: • Primary: Length of hospital stay• Secondary: Treatment for NAS, need for

multiple medications

MethodsMethods

• 86 opioid exposed term infants• Mothers receiving methadone or buprenorphine• Infants treated with morphine or methadone• If severe - additional medications given• A sample of blood or saliva collected from

each infant • Incidence and severity correlated with changes

in genetic profiles

ResultsResultsDEMOGRAPHICSWhite 98%

Maternal Methadone 64%

Maternal Buprenorphine 36%

Maternal Smoking 78%

Maternal Benzodiazepines 12%

LOS All Infants Mean 22.3 days

LOS Treated Infants Mean 31.6 days

Treatment for NAS 65%

Treated with >2 medications 24%

OPRM1 118A>G Results OPRM1 118A>G Results • AA vs AG/GG infants compared in models that

adjust for breastfeeding and study site• Those with the AG/GG genotype - treated less

frequently and had shorter LOS

OUTCOME UNADJUSTEDRESULTS

ADJUSTED RESULTS

P-VALUE

Infant Treated 72% vs 48% OR = 0.76 (CI 0.63, 0.96)

0.006

Mean LOS 24.1 vs 17.6 days - 8.5 days 0.009

COMT 158A>G ResultsCOMT 158A>G Results

• AA infants vs AG/GG infants in models that adjusted for breastfeeding and site

• AG/GG infants were treated less frequently and had shorter LOS than AA infants

OUTCOME UNADJUSTED RESULTS

ADJUSTED RESULTS

P-VALUE

Infant Treated 88% vs 60% OR = 0.79(CI 0.61, 0.99)

0.02

Mean LOS 31.1 vs 20.4 days - 10.8 days 0.005

ConclusionsConclusions

• NAS is a complex disorder with many factors contributing to the incidence and severity

• SNPs in the OPRM1 and COMT genes - reduced treatment and LOS

• No associations found with ABCB1 SNPs• Combining clinical risk factors with genetic

profiling would permit personalized genetic medicine and targeted treatment regimens

Challenges in Neonatal Drug Development Challenges in Neonatal Drug Development

• Most drugs used in newborn infants not FDA approved - safety and efficacy not established

• Small market, high liability, ethical concerns• Significant variability in NAS treatment protocols• Many NAS medications include alcohol or

propylene glycol • Concern for adverse long-term developmental

outcomes

Future DirectionsFuture Directions

• NIH Grant – “Improving Outcomes in Neonatal Abstinence Syndrome”

• Randomize infants to receive morphine or methadone (determine best practice)

• Evaluate long-term neurodevelopmental outcomes of infants treated for NAS

• Establish other genetic factors - Addiction Array (1350 SNPs for addiction disorders)

AcknowledgementsAcknowledgements• The Floating Hospital at Tufts Medical Center:

• Tufts Medical Center, Melrose Wakefield Hospital, Brockton Hospital, and Lowell General Hospital

• Ozlem Kasaroglu, Teresa Marino, Mario Cordova• CTRC Genomics Laboratory

• Eastern Maine Medical Center:• Staff at the EMMC • Hira Shrestha; Nicole Heller, Beth Logan, Deborah

Morrison

That’s All Folks!